Rain Oncology Overview
Valuation check: RAIN's ROE is 96.76%, above the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow96.76%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Rain Oncology (RAIN) currently reports a ROE of 96.76%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore Rain Oncology's ROE history and peer comparisons.
Rain Oncology's ROE of 96.76% is higher than the Healthcare sector average of 21.67%. That is roughly 346.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Rain Oncology's current 96.76% should be judged against Healthcare norms (sector average: 21.67%) and against RAIN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 96.76%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Rain Oncology, and consider following RAIN for alerts when major investors trade the stock.
Rain Oncology is classified in the Healthcare sector. On ROE, it currently shows 96.76% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RAIN with unrelated industries.
